| Generic name | Mogamulizumab |
| Brand name(s), other common name(s) | Poteligeo® |
| Drug type | Monoclonal antibody |
| How the drug is given | Intravenously (IV) |
Indications and Usage
Mogamulizumab is FDA approved for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
Side effects needing medical attention
The most common side effects of treatment with Poteligeo included rash, infusion-related reactions, fatigue, diarrhea, musculoskeletal pain and upper respiratory tract infection.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.